Home > Boards > US Listed > Biotechs > Actinium Pharmaceuticals, Inc. (ATNM)

NEWS -- Iomab-B One of Four Late Breaking

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Paulness Member Profile
 
Followed By 65
Posts 9,892
Boards Moderated 0
Alias Born 11/02/03
160x600 placeholder
Current Report Filing (8-k) Edgar (US Regulatory) - 6/7/2019 5:05:42 PM
Quarterly Report (10-q) Edgar (US Regulatory) - 5/10/2019 4:58:07 PM
Securities Registration: Employee Benefit Plan (s-8) Edgar (US Regulatory) - 5/10/2019 4:51:31 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 4/18/2019 5:25:44 PM
Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) Edgar (US Regulatory) - 4/18/2019 5:08:23 PM
Statement of Ownership (sc 13g) Edgar (US Regulatory) - 4/18/2019 11:52:54 AM
Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) Edgar (US Regulatory) - 4/17/2019 4:18:04 PM
Annual Report (10-k) Edgar (US Regulatory) - 3/15/2019 5:05:11 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 3/12/2019 5:26:30 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 3/7/2019 4:52:38 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 2/21/2019 4:48:55 PM
Amended Statement of Ownership (sc 13g/a) Edgar (US Regulatory) - 2/14/2019 2:20:32 PM
Actinium Initiates Novel Phase 1/2 Combination Trial of Actimab-A and Venetoclax PR Newswire (US) - 2/5/2019 8:00:00 AM
Actinium Initiates Second Dosing Cohort of Novel Combination Trial with Actimab-A and CLAG-M Salvage Regimen at Medical Colle... PR Newswire (US) - 2/4/2019 8:00:00 AM
Actinium Pharmaceuticals to Host Key Opinion Leader Breakfast on Targeted Conditioning for Bone Marrow Transplant and CAR-T o... PR Newswire (US) - 1/29/2019 8:00:00 AM
Actinium Pharmaceuticals, Inc. to Present at Noble Capital Markets' 15th Annual Investor Conference PR Newswire (US) - 1/25/2019 8:00:00 AM
Actinium Pharmaceuticals Appoints Accomplished Industry Executive Cynthia Pussinen as Executive Vice President of Technical O... PR Newswire (US) - 1/23/2019 8:00:00 AM
Actinium Successfully Completes First Module of Collaborative Research Program with Astellas; Second Module Initiated PR Newswire (US) - 1/17/2019 8:00:00 AM
Actinium Pharmaceuticals Appoints Qing Liang, PhD, DABR as Vice President, Head of Radiation Sciences to Further Innovation f... PR Newswire (US) - 1/16/2019 8:00:00 AM
Actinium Pharmaceuticals, Inc. to Present at the 2019 Biotech Showcase™ in San Francisco PR Newswire (US) - 1/3/2019 8:00:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 12/28/2018 5:11:58 PM
Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) Edgar (US Regulatory) - 12/28/2018 5:10:38 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 12/26/2018 5:03:31 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 12/21/2018 4:59:01 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 12/10/2018 4:15:25 PM
Paulness   Wednesday, 02/13/19 09:27:09 AM
Re: None
Post # of 1651 
NEWS -- Iomab-B One of Four Late Breaking Oral Presentations to be Presented at the 2019 Transplantation & Cellular Therapy Annual Meeting
  • Iomab-B and multiple abstracts selected for inclusion at leading medical conference focused on bone marrow transplant and cellular therapy
NEW YORK, Feb. 12, 2019 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) announced today that a presentation of data from the pivotal Phase 3 SIERRA trial of Iomab-B has been selected as one of four late breaking oral presentations at the 2019 TCT or Transplantation & Cellular Therapy Meetings™ of ASBMT and CIBMTR, which is being held February 20 – 24 in Houston, Texas. In addition, three abstracts related to Actinium's targeted conditioning pipeline have been accepted for poster presentations.

Sandesh Seth, Chairman and CEO of Actinium, said, "TCT is the ideal venue for us to present data and highlight our targeted conditioning programs as it is the pre-eminent medical meeting focused on bone marrow transplant and cellular therapy. We are excited to have multiple opportunities to highlight clinical data for Iomab-as well as update on Iomab-ACT, our newest program focused on lymphodepletion prior to CAR-T. In addition, we are involved with several events, educational and otherwise, that will enable us to educate a broad audience of investigators, researchers and potential partners about the SIERRA trial and our highly differentiated multi-disease, multi-target targeted conditioning pipeline. We expect this meeting to be a highly productive and consequential one for our company."

To see full PR with schedules view the original content here: http://www.prnewswire.com/news-releases/iomab-b-one-of-four-late-breaking-oral-presentations-to-be-presented-at-the-2019-transplantation--cellular-therapy-annual-meeting-300793634.html

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist